AI Terminal
Vetoquinol SA
Report Publication Announcement • Jan 3, 2024
1747_iss_2024-01-03_ebcb472e-dcfb-4cc4-a63b-94a54d8f1b09.pdf
Report Publication Announcement
Open in ViewerOpens in native device viewer
PRESS RELEASE
Lure January 3rd, 2024
2024 CALENDAR OF FINANCIAL COMMUNICATION
Vetoquinol published its calendar of financial communication for 2024.
| January 24, 2024 | 2023 Annual revenues (after market) |
|---|---|
| March 20, 2024 | 2023 Annual results (confcall after market) |
| April 29, 2024 | 2024 First quarter revenues (after market) |
| May 28, 2024 | Annual shareholders' meeting |
| June 6, 2024 | Dividend payment |
| September 12, 2024 | 2024 First semester results (confcall after market) |
| October 30, 2024 | 2024 Third quarter revenues (after market) |
Next update: Annual Sales 2023, January 24th, 2024 after market close
FOR MORE INFORMATION, CONTACT:
VETOQUINOL
Investor Relations Fanny Toillon Tel.: +33 (0)3 84 62 59 88 [email protected]
KEIMA COMMUNICATION
Investor & Media Relations Emmanuel Dovergne Tel.: +33 (0)1 56 43 44 63 [email protected]
VETOQUINOL Magny-Vernois 70200 Lure - France
www.vetoquinol.com
ABOUT VETOQUINOL
Vetoquinol is a leading global animal health company that supplies drugs and nonmedicinal products for the farm animals (cattle and pigs) and pet (dogs and cats) markets. As an independent pure player, Vetoquinol designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region. Since its foundation in 1933, Vetoquinol has pursued a strategy combining innovation with geographical diversification. The Group's hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. Vetoquinol employed 2,497 people as of June 30 th, 2023.
Vetoquinol has been listed on Euronext Paris since 2006 (symbol: VETO). The Vetoquinol share is eligible for the French PEA and PEA-PME personal equity plans.